How to Assess Airborne Mycotoxins for Inhalation Exposure
A practical guide to understanding how airborne mycotoxins relate to inhalation exposure and how to interpret airborne measurements in indoor environments.
Who This Guide Is For
This guide is written for Indoor Environmental Professionals, clinicians, consultants, and technically engaged property stakeholders who need to understand how airborne mycotoxin measurements should be obtained and interpreted when the environmental question concerns indoor inhalation exposure.
It explains what airborne mycotoxin results can and cannot show, how breathing-zone sampling differs from dust or surface testing, and how inhalation relevance is preserved during environmental assessment.
This guide does not define health thresholds, medical diagnoses, regulatory standards, or remediation requirements. It explains how airborne mycotoxin measurements should be interpreted within the physical and aerosol-science limits of what airborne testing represents.
What This Guide Explains About Airborne Mycotoxins
This guide focuses on how airborne mycotoxin measurements should be obtained and interpreted when evaluating indoor air–mediated exposure.
Airborne mycotoxin sampling is intended to characterize particle-associated mycotoxins present in the air occupants are breathing during the sampling period. It is not designed to measure historical contamination accumulated in dust reservoirs or localized residues on surfaces (Nazaroff, 2016; Morawska et al., 2013).
This guide explains how airborne sampling must be aligned with the breathing zone, inhalable particle fraction, and defined sampling interval to preserve inhalation relevance.
The Core Idea in Simple Terms
Before interpreting an airborne mycotoxin result, ask one question:
Does this sample represent what occupants were actually inhaling during the sampling period?
Airborne testing answers inhalation questions only when suspended particles are measured within the occupied breathing zone under conditions representative of normal indoor activity. Sampling outside the breathing zone or under non-representative conditions may detect contamination, but it does not represent inhalation exposure (Nazaroff, 2016).
Breathing Zone Rule:
If it doesn’t represent the breathing zone under normal conditions, it doesn’t represent inhalation exposure.
Two Different Questions: Airborne Exposure vs. Reservoir Contamination
Indoor mycotoxin investigations often mix two distinct environmental questions.
1. Airborne exposure within the breathing zone.
This question asks whether particle-associated mycotoxins are present in the air occupants inhale during the sampling interval. Airborne measurements evaluate inhalation-relevant aerosol conditions rather than accumulated contamination (Morawska et al., 2013).
2. Reservoir contamination in dust or on surfaces.
Dust and surface measurements characterize accumulated residues integrated over time or localized to specific materials. These domains describe environmental reservoirs rather than inhalation exposure at a specific time (Nazaroff, 2016).
Confusing these questions leads to misinterpretation of airborne results.
| Question Being Asked | Airborne Domain | Dust / Surface Domain |
|---|---|---|
| What is being measured? | Suspended particles in the breathing zone | Accumulated residues |
| Time relevance | Real-time snapshot | Integrated over time |
| Exposure meaning | Inhalation conditions | Reservoir magnitude |
| Represents what? | What occupants are breathing | What has settled or accumulated |
The Airborne Domain in Indoor Mycotoxin Testing
Part C focuses on one analytical domain: the airborne domain.
The airborne domain represents suspended particulate matter within the occupied breathing zone during a defined sampling interval. It reflects dynamic aerosol conditions influenced by airflow, disturbance, deposition, filtration, and ventilation rather than long-term accumulation (Morawska et al., 2013; Nazaroff, 2016).
Airborne measurements therefore describe time-specific inhalation conditions, not historical contamination or reservoir magnitude.
Why Breathing-Zone Positioning Matters
Airborne mycotoxins are typically associated with fine and inhalable particles that remain suspended and follow indoor airflow patterns. Particle concentrations vary vertically and spatially due to settling, resuspension, and air mixing (Nazaroff, 2016).
Air sampled near floors, ceilings, walls, or emission sources may differ substantially from air within the breathing zone. Sampling location therefore determines whether airborne measurements represent inhalation conditions.
Airborne measurements represent inhalation exposure only when collected within the occupied breathing zone.
Breathing-zone positioning preserves exposure alignment, whereas near-source placement may detect contamination potential but distort exposure interpretation.
Breathing Zone Rule:
If the sample was not collected in the breathing zone, it does not represent inhalation exposure.
Why Particle Size Matters in Airborne Mycotoxin Testing
Airborne mycotoxin signals are predominantly particle-associated rather than gaseous. The inhalable fraction includes particles capable of entering the nose and mouth during breathing. Larger particles settle rapidly, whereas fine particles remain suspended and are more likely to be inhaled (ISO 7708; CEN EN 481).
Airborne sampling intended to represent inhalation exposure must therefore capture the inhalable particle fraction, not merely respirable or bulk dust fractions. If particle-size capture does not reflect inhalable behavior, inhalation interpretation may be distorted (Morawska et al., 2013).
| Particle Fraction | What It Represents | Inhalation Relevance |
|---|---|---|
| Inhalable | Particles entering nose/mouth | Required for exposure interpretation |
| Respirable | Deep lung deposition fraction | Not equivalent to total inhalation exposure |
| Bulk dust | Settled material | Reservoir contamination, not airborne exposure |
Why Time of Sampling Matters
Airborne particle concentrations change with occupancy, disturbance, ventilation, and environmental state. Resuspension from movement, HVAC operation, cleaning, humidity shifts, and airflow patterns all influence airborne mycotoxin detection (Nazaroff, 2016).
Because of this variability, airborne measurements represent a defined sampling interval, not a permanent environmental condition.
Airborne non-detect results indicate concentrations below detection limits during the sampling period — not the absence of contamination in the building.
Sampling Interval Principle:
Airborne results describe conditions during the sampling period, not long-term building status.
Common Misunderstandings About Airborne Mycotoxin Testing
Dust reservoirs and airborne particles behave differently in indoor environments. Settled dust can accumulate contamination without continuous airborne presence. Airborne detection therefore cannot be inferred from dust findings, and dust contamination does not guarantee inhalation exposure during normal occupancy (Nazaroff, 2016).
Similarly, absence of airborne detection during one interval does not exclude episodic airborne presence under different disturbance or ventilation conditions. Airborne testing reflects conditions during sampling rather than all possible indoor states (Morawska et al., 2013).
Sampling near visible mold or emission sources measures localized release potential rather than breathing-zone exposure. Inhalation relevance requires breathing-zone alignment.
Professional Interpretation of Airborne Results
Airborne mycotoxin results describe particle-associated chemical presence within the inhalable fraction under defined environmental conditions. They do not describe historical contamination, reservoir magnitude, or exposure outside the sampling interval (Nazaroff, 2016).
Airborne results should therefore be interpreted as time-specific inhalation indicators, not building-wide contamination measures.
Airborne vs Dust vs Surface in Exposure Assessment
- Airborne testing answers inhalation questions.
- Dust testing answers reservoir questions.
- Surface testing answers localized contamination questions.
Each domain represents different physical processes and temporal integration scales (Morawska et al., 2013; Nazaroff, 2016).
Agreement across domains strengthens interpretation. Divergence reflects domain behavior rather than analytical error. Airborne exposure cannot be inferred from dust or surface findings without direct airborne measurement.
| Domain | Primary Question Answered | Time Scale | Exposure Meaning |
|---|---|---|---|
| 🌬️ Airborne | What occupants are inhaling now | Defined sampling interval | Inhalation exposure |
| 🧹 Dust | What has accumulated over time | Integrated reservoir | Contamination magnitude |
| 🧪 Surface | What is present on specific materials | Localized | Release potential |
Relationship to the Scientific Framework
This guide provides a plain-language interpretation of the Part C technical white paper, which operationalizes inhalation-aligned airborne assessment within the Exposure-Aligned Analytical Domain Framework for Indoor Mycotoxins (EADF-IM).
The Part C white paper defines:
- Breathing-zone alignment requirements
- Inhalable-fraction sampling conditions
- Temporal limits of airborne interpretation
- Placement constraints for exposure relevance
- Boundaries between airborne and reservoir domains
For full scientific definitions and references, consult the Part C technical white paper:
/preprints/2026c-inhalation-aligned-mycotoxin/
Final Takeaway
Airborne mycotoxin testing is meaningful only when aligned with inhalation conditions. If the question concerns what occupants are breathing, sampling must occur within the breathing zone, capture inhalable particles, and represent normal indoor conditions during the defined sampling interval.
Different analytical domains answer different questions. Airborne testing answers inhalation exposure only when airborne alignment is preserved.
Need Help Interpreting Airborne Mycotoxin Results
If you are unsure whether airborne testing is appropriate or how to interpret results in context, a short consultation can help clarify next steps. This discussion is informational only and does not provide medical or regulatory advice.
References and Scientific Basis
This guide is based on the Part C technical white paper and established literature in aerosol physics and indoor exposure science.
- Ritacco, M. (2026). Operationalizing the Exposure-Aligned Analytical Domain Framework for Indoor Mycotoxins (EADF-IM): Mechanistic Foundations and Field Implementation of Inhalation-Aligned Airborne Assessment. Respirare Labs Technical White Paper.
/preprints/2026c-inhalation-aligned-airborne-assessment/ - Morawska, L., Afshari, A., Bae, G.-N., et al. (2013). Indoor aerosols: From personal exposure to risk assessment. Indoor Air, 23(6), 462–487. https://pubmed.ncbi.nlm.nih.gov/23574389/
- Nazaroff, W. W. (2016). Indoor bioaerosol dynamics. Indoor Air, 26(1), 61–78. https://pmc.ncbi.nlm.nih.gov/articles/PMC7165847/
- ISO. (1995). ISO 7708: Air quality — Particle size fraction definitions for health-related sampling. https://www.iso.org/standard/14231.html
- CEN. (1993). EN 481: Workplace atmospheres — Size fraction definitions for measurement of airborne particles.
About this Guide
This guide interprets Respirare Labs’ 2026 Part C preprint on inhalation-aligned airborne mycotoxin assessment.